Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node

Shots:

• The approval is based on P-III EORTC1325/KEYNOTE-054 trial results assessing Keytruda (pembrolizumab,200mg, q3w) vs PBO in 1019 patients in the ratio (1:1) with completely resected stage IIIA, IIIB or IIIC melanoma for 1yr or until disease recurrence or unacceptable toxicity
• P-III EORTC1325/KEYNOTE-054 trial results: 43% reduction in the risk of disease recurrence or death; improvement in recurrence-free survival (RFS) benefit
• Keytruda (pembrolizumab) 100mg IV is a mAb, used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2, further activating T lymphocytes

Click here to read full press release/ article| Ref: Merck | Image: Twitter